BAM
MRTX

Bellevue Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bellevue Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15
Closed -$1K – 499
2022
Q3 		$1K Hold
15
– – ﹤0.01% 493
2022
Q2 		$1K Hold
15
– – ﹤0.01% 496
2022
Q1 		$1K Sell
15
-3
-17% -$307 ﹤0.01% 531
2021
Q4 		$3K Sell
18
-1
-5% -$155 ﹤0.01% 466
2021
Q3 		$3K Hold
19
– – ﹤0.01% 488
2021
Q2 		$3K Buy
19
+8
+73% +$1.28K ﹤0.01% 486
2021
Q1 		$2K Buy
+11
New +$2.18K ﹤0.01% 609

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Asset Management's MRTX Position: Q4 2022 in Review

Bellevue Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 15 shares — an estimated $1K sold.

Bellevue Asset Management first reported a position in MRTX in Q1 2021 and held it in 7 quarters. The position peaked at $3K in Q4 2021. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • Bellevue Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Bellevue Asset Management sold 15 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
  • Bellevue Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Bellevue Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $3K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Bellevue Asset Management's 13F filing for Q4 2022, filed 23 Jan 2023.